Daniel Vitt, Ph.D., joined Immunic in January 2017, and subsequent to the company’s reverse takeover transaction with Vital Therapies in 2019, has served as Chief Executive Officer, President and Director of Immunic, Inc. Previously, he was Chief Scientific Officer and Chief Development Officer of 4SC AG, a publicly traded company based in Germany that he co-founded in 1997. While there, he successfully grew the company from the research stage into an advanced therapeutic development company with several clinical-stage product candidates in the pipeline.
Dr. Vitt studied chemistry in Siegen and Würzburg, Germany, and graduated from the University of Würzburg, where he focused on quantum-chemical calculations of organic reactions. He received his Ph.D. from the Institute of Organic Chemistry at the University of Würzburg, where he focused on molecular design of small molecule therapeutics.
Dr. Vitt is currently a member of the advisory board of the venture capital fund “Wachstumsfond Bayern 2,” managed by Bayern Kapital GmbH. In 2018, he also co-founded Brauhaus Germering GmbH, a local German specialty brewery.
What is Daniel Vitt's net worth?
The estimated net worth of Daniel Vitt is at least $410,795.93 as of November 22nd, 2022. Dr. Vitt owns 376,877 shares of Immunic stock worth more than $410,796 as of November 14th. This net worth approximation does not reflect any other assets that Dr. Vitt may own. Additionally, Dr. Vitt receives a salary of $869,960.00 as CEO at Immunic. Learn More about Daniel Vitt's net worth.
What is Daniel Vitt's salary?
How do I contact Daniel Vitt?
Has Daniel Vitt been buying or selling shares of Immunic?
Daniel Vitt has not been actively trading shares of Immunic within the last three months. Most recently, on Tuesday, November 22nd, Daniel Vitt bought 8,000 shares of Immunic stock. The stock was acquired at an average cost of $1.35 per share, with a total value of $10,800.00. Following the completion of the transaction, the chief executive officer now directly owns 376,877 shares of the company's stock, valued at $508,783.95. Learn More on Daniel Vitt's trading history.
Who are Immunic's active insiders?
Are insiders buying or selling shares of Immunic?
In the last twelve months, Immunic insiders bought shares 1 times. They purchased a total of 87,300 shares worth more than $100,395.00. The most recent insider tranaction occured on November, 12th when Director Richard Alan Rudick bought 87,300 shares worth more than $100,395.00. Insiders at Immunic own 3.0% of the company.
Learn More about insider trades at Immunic. Information on this page was last updated on 11/12/2024.
